Stockscreener 앱 받기
10.77
2.09%
-0.23
시간 외 거래:
10.77
전일 마감가:
$11.00
열려 있는:
$10.99
하루 거래량:
271.45K
Relative Volume:
0.90
시가총액:
$577.24M
수익:
$2.22M
순이익/손실:
$-40.51M
주가수익비율:
-8.3833
EPS:
-1.2847
순현금흐름:
$-46.53M
1주 성능:
+3.66%
1개월 성능:
-34.49%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$10.31
$11.79
1주일 범위
$9.2901
$11.79
52주 변동 폭
$9.2901
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
명칭
Upstream Bio Inc
전화
781-208-2466
주소
890 WINTER STREET, SUITE 200, WALTHAM
UPB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
10.77 | 577.24M | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-05 | 개시 | JP Morgan | Overweight |
| 2024-11-05 | 개시 | Piper Sandler | Overweight |
| 2024-11-05 | 개시 | TD Cowen | Buy |
| 2024-11-05 | 개시 | William Blair | Outperform |
Upstream Bio Inc 주식(UPB)의 최신 뉴스
Upstream Bio (NASDAQ:UPB) Trading 9.4% HigherHere's What Happened - MarketBeat
Chronic Rhinosinusitis with Nasal Polyps Pipeline 2024: FDA - openPR
Upstream Bio (UPB) Expected to Announce Earnings on Thursday - MarketBeat
Upstream Bio (UPB) Projected to Post Earnings on Thursday - Defense World
Moody Aldrich Partners LLC Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB) - MarketBeat
Upstream Bio (NASDAQ:UPB) Sets New 52-Week Low – Time to Sell? - Defense World
Upstream Bio (NASDAQ:UPB) Trading Down 3.9%Time to Sell? - MarketBeat
Upstream Bio (NASDAQ:UPB) Sets New 52-Week LowTime to Sell? - MarketBeat
Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024 - News & Insights
Upstream Bio (NASDAQ:UPB) Trading Down 10.4%Time to Sell? - MarketBeat
Upstream Bio (NASDAQ:UPB) Sets New 1-Year LowWhat's Next? - MarketBeat
Sionna Therapeutics Appoints Dr. Marcella Kuhlman Ruddy and Dr. Jo Viney to its Board of Directors - citybiz
Upstream Bio (NASDAQ:UPB) Stock Price Down 7%What's Next? - MarketBeat
Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Upstream Bio (NASDAQ:UPB) Trading Up 8.5%Here's Why - MarketBeat
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
Single-use Bioprocessing Market Size to Hit USD 146.84 Bn by 2034 - Precedence Research
Upstream Bio (NASDAQ:UPB) Trading Down 3%Here's What Happened - MarketBeat
Upstream Bio (NASDAQ:UPB) Shares Up 5.7%Time to Buy? - MarketBeat
Should You Scoop Up This 'Strong Buy' Biotech Before December 23? - MSN
Amgen Inc (AMGN-Q) QuotePress Release - The Globe and Mail
Upstream Bio (NASDAQ:UPB) Reaches New 52-Week LowShould You Sell? - MarketBeat
Newly Public Biotech Startup Hires Life Sciences Veteran as GC - Law.com
Upstream Bio (NASDAQ:UPB) Shares Gap DownWhat's Next? - MarketBeat
Upstream Bio Appoints Allison Ambrose as General Counsel - citybiz
Upstream Bio (NASDAQ:UPB) Shares Down 5%Time to Sell? - MarketBeat
Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation (UPB) - Seeking Alpha
Upstream Bio To Be Added To Russell 2000 - MENAFN.COM
Upstream Bio to be Added to Russell 2000 - Baystreet.ca
Upstream Bio Announces Addition to Russell 2000® Index - GlobeNewswire
Upstream Bio to Join Russell 2000® Index, Gaining Access to $10.5T Benchmark-Linked Assets - StockTitan
After Making the IPO Jump, Biotechs Landed On a Slippery Slope - BioSpace
Upstream Bio: Attractive, But Let's Wait For More Data And Lock-Up Expiry (NASDAQ:UPB) - Seeking Alpha
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - MSN
ExxonMobil Announces New Upstream Leader - Rigzone News
Upstream Bioprocessing Market to Reach USD 82.10 Billion by 2032 from USD 22.79 Billion in 2023 | CAGR of 15.35% - GlobeNewswire
Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Upstream Bio CEO to Present at Piper Sandler Healthcare Conference Dec 3 | UPB Stock News - StockTitan
Upstream Bioprocessing Industry Analysis and Forecast, - GlobeNewswire
Upstream Bio, Inc.’s (NASDAQ:UPB) Quiet Period Set To End on November 20th - Defense World
Upstream Bio, Inc.'s (NASDAQ:UPB) Quiet Period Set To End on November 20th - MarketBeat
Brokers Set Expectations for Upstream Bio Q4 Earnings - MarketBeat
Upstream Bio Advances Clinical Trials, Strengthens Financials - TipRanks
Tezspire Phase III Nasal Polyp Data May Lead To Second Indication - Scrip
William Blair Weighs in on Upstream Bio Q4 Earnings - Defense World
Upstream Bio Inc (UPB) Quarterly 10-Q Report - Quartz
Upstream Bio Inc (UPB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):